483
ACS Dobfar SPA (Plant #2)ACS Dobfar SPA (Plant #2) – FDA 483, Jul 18, 2017
Record Details
An FDA inspection of ACS Dobfar s.p.a. (Plant #2) in Milan, Italy, revealed significant deficiencies in their drug manufacturing processes. Observations included a lack of adequate process validation for drug products, insufficient controls to prevent cross-contamination, and failures in procedures designed to prevent microbiological contamination of sterile drug products. These issues indicate a high potential for product quality and safety concerns.
View Company Profile
ID · a19a3f04-faa5-44c2-865a-35dc99cfd880
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.